🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. METHOTREXATE, METHOTREXATE, DESOXIMETASONE, TACROLIMUS, placebo, Acidum folicum Léčiva 10 mg obalené tablety, FOLIC ACID

    Medac Gesellschaft fuer klinische Spezialpraeparate mbH

    moderate to severe atopic dermatitis

    phase 3 small molecule active

    1 trial

  2. METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab

    Genmab A/S

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. METHYLPREDNISOLONE , PREDNISONE , Gazyvaro 1,000 mg concentrate for solution for infusion., Obinutuzumab placebo, Myfenax 500 mg film-coated tablets, DIPHENHYDRAMINE , PARACETAMOL

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 3 small molecule active

    1 trial

  4. METYRAPONE ESTEVE 250 mg, capsule molle, Placebo of metyrapon 250 mg

    Pari Pharma GmbH

    Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)

    phase 3 small molecule active

    1 trial

  5. MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)

    Seqirus (Australia) Pty Ltd

    Influenza

    phase 3 mab completed

    1 trial

  6. MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  7. MIDAZOLAM , CEDACONDA 100 % V/V, liquide pour inhalation par vapeur, PROPOFOL

    Pari Pharma GmbH

    Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.

    phase 3 small molecule active

    1 trial

  8. MIDAZOLAM , PROPOFOL , ROCURONIUM BROMIDE , Cipepofol Injectable Emulsion, FENTANYL , SEVOFLURANE , PROPOFOL

    Lacuna Pharma Pty Ltd

    General anaesthesia

    phase 3 small molecule active

    1 trial

  9. MIDOSTAURIN, ARACYTIN 500 mg/10 ml Polvere e Solvente per Soluzione Iniettabile, DAUNORUBICIN HYDROCHLORIDE

    Fondazione Telethon ETS

    Acute Myeloid Leukemia (LMA) with FLT3 mutation

    phase 3 small molecule active

    1 trial

  10. MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT

    Lacuna Pharma Pty Ltd

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  11. MITOMYCIN , JNJ-42756493, GEMCITABINE

    Janssen-Cilag International N.V.

    High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations

    phase 3 small molecule active

    1 trial

  12. MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  13. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial

  14. MK-0616, Placebo to MK-0616 - Tablet

    Merck Sharp and Dohme

    ASCVD - Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  15. MK-1084, MK-3475A, CARBOPLATIN , PEMETREXED , MK-1084, CISPLATIN , Placebo for MK-1084

    Merck Sharp and Dohme

    Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC

    phase 3 small molecule active

    1 trial

  16. MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 small molecule active

    1 trial

  17. MK-2870, GEMCITABINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , -, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    Merck Sharp and Dohme

    Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10

    phase 3 small molecule active

    1 trial

  18. MK-2870, PACLITAXEL , -, PARACETAMOL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , CISPLATIN , GEMCITABINE , -, PEMETREXED

    Merck Sharp and Dohme

    Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])

    phase 3 small molecule active

    1 trial

  19. MK-2870, PACLITAXEL ALBUMIN-BOUND, -, PACLITAXEL , -, -, DOXORUBICIN , PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  20. MK-2870, PARACETAMOL , TOPOTECAN , -, TISOTUMAB VEDOTIN, IRINOTECAN , PEMETREXED , -, -, GEMCITABINE , MK-2870, VINORELBINE

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 small molecule active

    1 trial

  21. MORPHINE SULFATE, Placebo tablets morphine sulfate 10mg

    Pari Pharma GmbH

    patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis.

    phase 3 small molecule active

    1 trial

  22. MYCOHYDRALIN 500 mg, capsule vaginale, FLAGYL 500 mg, comprimé pelliculé, ZITHROMAX 250 mg, comprimé pelliculé, ROCEPHINE 1 g/3,5 ml, poudre et solvant pour solution injectable (IM), GRANUDOXY 100 mg, comprimé pelliculé sécable

    ISTA Pharma Limited

    Bacterial vaginosis, High risk preterm birth pregnancy, Vaginal flora abnormalities

    phase 3 small molecule active

    1 trial

  23. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  24. MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources